Rallybio Halts Development of Lead FNAIT Program Following Phase 2 Failure

Rallybio RLYB212, Fetal and neonatal alloimmune thrombocytopenia (FNAIT), Phase 2 clinical trial, Maternal immune disorder therapy, Biotech pipeline shift

GSK’s Penmenvy Gains FDA Approval, Joining Pfizer in 5-in-1 Meningococcal Vaccine Market

Penmenvy, GSK, FDA approval, meningococcal vaccine, 5-in-1 vaccine, Pfizer, Penbraya, invasive meningococcal disease (IMD), adolescents and young adults